SEARCH · Search PubMed
Results for “Memantine”
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
[The effects of milkvetch and memantain on the synthesis of cerebral PAF in neonatal rats with hypoxic-ischemic reperfusion].
Explore the source record for details and available documents.
FDA approves groundbreaking Alzheimer's drug.
Explore the source record for details and available documents.
Society of neuroscience-33rd annual meeting: metabotropic glutamate receptors.
Explore the source record for details and available documents.
Academic highlights: emerging therapeutic strategies in Alzheimer's disease.
Explore the source record for details and available documents.
Drug for moderate to advanced Alzheimer's approved.
Explore the source record for details and available documents.
First drug for moderate-to-severe Alzheimer's.
Explore the source record for details and available documents.
American Chemical Society--227th Annual Meeting. NMDA receptor. 28 March - 1 April 2004, Anaheim, CA, USA.
Explore the source record for details and available documents.
[New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].
Explore the source record for details and available documents.
[Effect of drugs against dementia].
Explore the source record for details and available documents.
[New informations on medical treatment for normal-tension glaucoma].
Explore the source record for details and available documents.
[NMDA receptor antagonists: a new treatment for neuropathic pain].
Explore the source record for details and available documents.
Vascular dementia. Advances in nosology, diagnosis, treatment and prevention.
Ischemic or hemorrhagic cerebrovascular disease (CVD) produces injury of brain regions important for executive function, behavior, and memory leading to decline in cognitive functions and vascular dementia (VaD). Cardiovascular disease may cause VaD from hypoperfusion of susceptible brain areas. CVD may worsen degenerative dementias such as Alzheimer disease (AD). Currently, the global diagnostic category for cognitive impairment of vascular origin is vascular cognitive disorder (VCD). VCD ranges from vascular cognitive impairment (VCI) to VaD. The term VCI is limited to cases of cognitive impairment of vascular etiology, without dementia; VCI is equivalent to vascular mild cognitive impairment (MCI). Risk factors for VaD include age, hypertension, diabetes, smoking, cardiovascular disease (coronary heart disease, congestive heart failure, peripheral vascular disease), atrial fibrillation, left ventricular hypertrophy, hyperhomocysteinemia, orthostatic hypotension, cardiac arrhythmias, hyperfibrinogenemia, sleep apnea, infection, and high C-reactive protein. Research on biomarkers revealed increased CSF-NFL levels in VaD, whereas CSF-tau was normal. CSF-TNF-alpha, VEGF, and TGF-beta were increased in both AD and VaD. VaD shows low CSF acetylcholinesterase levels. This condition responds to acetylcholinesterase inhibitors, confirming the central role of cholinergic deficit in its pathogenesis. Evidence strongly suggests that control of vascular risk factors, in particular hypertension, could prevent VaD.
[Music and art therapy--a taboo topic in therapy of dementia?].
Explore the source record for details and available documents.
Combination drug therapies for AD: progress is slow, but we must keep trying.
Explore the source record for details and available documents.
Antidementia agents: what is important in this class.
Explore the source record for details and available documents.